Stock Ratings / Health Care / ORGO / earnings

OKUR (46) UNCY (45) IMUX (38) VTVT (33) ⌘ Pro Terminal →

Organogenesis Holdings Inc. (Class A) (ORGO) Next Earnings Date & Expected ±12.5% Move

Q: Where is ORGO trading relative to its 50-day, 200-day, and 52-week technical levels?

ORGO last traded at $0.77 (-6.20% on volume of 760,317 shares), positioning the stock -42.11% below its 50-day simple moving average ($1.33) and -67.37% below its 200-day simple moving average ($2.36). Across its 52-week range of $0.73 to $7.08, ORGO sits at the 0.6% percentile with a 14-day RSI of 15.6 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.00 to $0.87).

Q: When is ORGO's next earnings date?

Based on SEC filing cadence, Organogenesis Holdings Inc. (Class A) (ORGO)'s next quarterly reporting window is estimated around Dec 30, 2026.

Q: How much is ORGO stock expected to move on earnings?

Volatility modeling currently projects a ±12.5% event move for ORGO, spanning a range between $1 and $0.87.

$0.77 -6.20% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $0.76

Organogenesis Holdings Inc. (Class A) (ORGO) carries a Roarable Rating of D (Sell) with 50/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record: Scores of 50/100 (D) historically posted market-perform odds over rolling 90-day windows (-1.4% avg 90D alpha vs SPY) →

ROARABLE D • SELL / AVOID Cap $105.4M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on ORGO Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is ORGO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, Organogenesis Holdings Inc. (Class A) (NASDAQ: ORGO) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 50/100 at a spot price of $0.77 (-6.20% 1D, market cap $105.4M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 13/20, Executive Insider Alignment 9/20, FRED Macro Regime Fit 12/20, and SEC Balance-Sheet Forensics 8/20. Across 1016 tracked Health Care issuers, ORGO ranks #298 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does ORGO compare to OKUR and UNCY in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ORGO carries a Roarable D (50/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of 17.1%. By comparison, OKUR (OnKure Therapeutics Inc. (Class A)) holds a D grade (46/100 RQD, P/E N/A, ROIC -35.0%, cap $106.1M) and UNCY (Unicycive Therapeutics Inc.) posts a D grade (45/100 RQD, P/E N/A, ROIC -35.0%, cap $106.1M). Among the 5-stock peer group, ORGO leads on earnings multiple (N/A) while ORGO leads on capital efficiency (17.1% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for ORGO?

▼

Per ORGO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001661181), Organogenesis Holdings Inc. (Class A) generated $564.2M in revenue (+17.0% YoY), $37.0M in net income, and -$24.5M in free cash flow against $598.7M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $0.76 (-1.31%)🧬 Disciplined Float (+1.08% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 50/100 (D) historically posted market-perform odds over rolling 90-day windows (-1.4% avg 90D alpha vs SPY • 49.3% hit rate — wait for RQD ≥ 70 breakout).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D

2-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D · Rk D+

Each axis scored 0–20

12M PRICE TARGET CONE-3.9% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ORGO)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (50/100 Composite)

🔍 WHY ORGO SCORES 50/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Whale & Options Positioning+13/20 pts (26% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▲ #2 Bullish Driver: Macro Regime Fit+12/20 pts (24% of score)

FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 15.6 (OVERSOLD (<32))

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution8/20 pts (-12 pt drag)

Disciplined Float (+1.08% YoY Shares) & executive Form 4 sales trim 12 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade C$1.23-17.1% Next Q

Q2 (-2Q)

Grade C$1.02-7.8% Next Q

Q3 (-1Q)

Grade C-$0.94-18.1% Next Q

Current

Grade D$0.77-1.4% Hist 90D α

Trajectory: C (58) → D (50)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a ORGO Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While ORGO currently carries a cautious 50/100 (D) rating due to Insider Conviction & Share Dilution (8/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.33) and Max Pain ($0.81) forces dealer call-delta covering toward $7.43.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+1.08% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $ORGO• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “ORGO Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 50%NO 50%Trade / Inspect Odds →

NEXT EST. WINDOW: Dec 30, 2026 (~57 DAYS)

Historical OHLCV Volatility ±12.5% Swing Band

±$0.10 Expected Swing

MODEL EARNINGS SETUP GAUGE

ORGO Quantitative Pre-Earnings Setup: 50/100

Trailing EPS: $4.25 • YoY Revenue Growth: 17%

Model Bullish Setup (50/100)Model Risk Weight (50/100)

Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).

LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):

Recent SEC Reported Revenue, Net Profit & Diluted EPS Cadence

Period	Filed	Revenue	Net Profit	Free Cash Flow	Gross Margin
FY 2025	2025-12-31	$564.2M	$37.0M	-$24.5M	52%
FY 2024	2024-12-31	$482.0M	$900.0K	$4.2M	76%
FY 2023	2023-12-31	$433.1M	$4.9M	$30.9M	52%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ORGO)

✓Walkthrough of ORGO's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

ORGO // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -69.92%🛡️ HOLDING TREND SUPPORT

2026-11-02O $0.78H $0.80L $0.73C $0.77VOL 310.2K

RES: $2.53SUP: $0.71SMA50: $1.33SMA200: $2.36

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ORGO Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 ORGO Butterfly Map → + Track ORGO →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +17.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on ORGO today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for ORGO. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for ORGO today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ORGO)

Health Care Rank #298 of 1016 ⚔️ OKUR vs ORGO Full Matrix →

1. Head-to-Head Health Care Peer Comparison (ORGO vs. OKUR, UNCY, IMUX, VTVT)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Organogenesis Holdings Inc. (Class A) (ORGO) ranks #298 by composite RQD confidence (50/100, grade D) and #655 by equity capitalization ($105.4M). Within this direct 5-issuer industry benchmark cohort, ORGO leads on earnings valuation at N/A trailing P/E, while ORGO leads on capital efficiency and profitability with 17.1% ROIC and — gross margin. ORGO currently leads its immediate peer cohort in composite quantitative strength at 50/100 (D).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
ORGO ACTIVE Organogenesis Holdings Inc. (Class A)	D	50/100	—	—	17.1%	-6.20%	$105.4M	Benchmark Subject
OKUR OnKure Therapeutics Inc. (Class A)	D	46/100	—	—	-35.0%	0.00%	$106.1M	/okur-vs-orgo →
UNCY Unicycive Therapeutics Inc.	D	45/100	—	—	-35.0%	-1.84%	$106.1M	/uncy-vs-orgo →
IMUX Immunic Inc.	D-	38/100	—	—	-35.0%	-3.66%	$106.4M	/imux-vs-orgo →
VTVT vTv Therapeutics Inc. (Class A)	E	33/100	—	—	-35.0%	-4.59%	$104.3M	/vtvt-vs-orgo →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001661181

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Organogenesis Holdings Inc. (Class A) (ORGO) reported GAAP revenue of $564.2M (+17.0% vs. FY2024 revenue of $482.0M , and +30.3% cumulative change since FY2023) , GAAP net income of $37.0M, operating cash flow of -$10.3M, and free cash flow of -$24.5M (-685.7% YoY). On the balance sheet, ORGO closed FY2025 with $598.7M in total assets against $0 in total debt (Altman Z-Score: 2.09, Piotroski F-Score: 4/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$564.2M	$37.0M	-$10.3M	-$24.5M	$598.7M	—
FY2024 (FY)	2024-12-31	$482.0M	$900.0K	$14.2M	$4.2M	$497.9M	—
FY2023 (FY)	2023-12-31	$433.1M	$4.9M	$30.9M	$30.9M	—	—

3. ORGO Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ORGO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does ORGO compare to OKUR and UNCY in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for ORGO?

Where is ORGO trading relative to its 50-day, 200-day, and 52-week technical levels?

ORGO last traded at $0.77 (-6.20% on volume of 760,317 shares), positioning the stock -42.11% below its 50-day simple moving average ($1.33) and -67.37% below its 200-day simple moving average ($2.36). Across its 52-week range of $0.73 to $7.08, ORGO sits at the 0.6% percentile with a 14-day RSI of 15.6 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.00 to $0.87).

ORGO Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

When is ORGO's next earnings date?

Based on SEC filing cadence, Organogenesis Holdings Inc. (Class A) (ORGO)'s next quarterly reporting window is estimated around Dec 30, 2026.

How much is ORGO stock expected to move on earnings?

Volatility modeling currently projects a ±12.5% event move for ORGO, spanning a range between $1 and $0.87.

Direct Sub-Reports: ORGO RQD Cockpit ORGO 12M Forecast ORGO Earnings & Move ORGO Dividends & DRIP ORGO Insiders & 13F ORGO Whale Options ORGO Profit Sankey ORGO News & Why

ROARABLE RATING BRIEF • RQD 50/100 (D) ✓ STAGE-C NUMBER FIREWALL VERIFIED

ORGO — Organogenesis Holdings Inc. (Class A): What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:43:56Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, ORGO scores 50 out of 100, a letter grade of D, with the verdict label "Roarable Sell — Underperform / Distribution Warning." The five pillars are:

Fundamental Cash Engine: 8 / 20. Per the Roarable RQD rating, this pillar reflects ROIC of 17.1% alongside an FCF yield of -23.21%. The divergence matters: returns on invested capital look respectable on paper, but the company is not converting that into free cash flow to shareholders at the current valuation.
Whale 13F Flow: 13 / 20. Per the Roarable RQD rating, this pillar captures institutional accumulation and options positioning. It is the strongest pillar in the set, indicating some institutional interest, though the source does not itemize the holdings behind it.
Insider Conviction: 8 / 20. Per the Roarable RQD rating, this pillar reflects SEC Form 4 and Congressional PTR cluster flow. The score is weak, signaling limited insider conviction in either direction in the source data.
Macro Regime Fit: 12 / 20. Per the Roarable RQD rating, beta is 1.0 with a sector sensitivity assessment. The stock is assessed as moving in line with the market, offering neither defensive nor high-beta characteristics.
Forensic Balance Sheet: 9 / 20. Per the Roarable RQD rating, the Altman Z-Score is 2.09, the Piotroski F-Score is 4/9, and Debt/Equity is 0.5. These readings place the balance sheet in a middling-to-weak position.

For a prospective investor evaluating the stock today, the implications are mixed but lean cautious. The upside case rests on the 17.1% ROIC and the institutional-flow pillar. The valuation tradeoff is that the negative FCF yield means the market price is not currently supported by cash generation, and the equity's low absolute price combined with a $105.4M market capitalization points to a small-cap profile with associated liquidity and volatility considerations. The overall RQD grade of D reflects that the weaker pillars (cash engine, insider conviction, forensic balance sheet) outweigh the institutional-flow strength.

Financial Trend

Period	Revenue	Operating Income	Net Income	EPS	FCF	Cash	Debt
FY 2025	$564.2M	$44.7M	$37.0M	N/A	$-24.5M	$93.7M	N/A
FY 2024	$482.0M	$-1.3M	$0.9M	N/A	$4.2M	$135.6M	N/A
FY 2023	$433.1M	$12.5M	$4.9M	N/A	$30.9M	N/A	N/A

Per the SEC financials, revenue grew from $433.1M (FY 2023) to $564.2M (FY 2025), and operating income moved from $12.5M to $44.7M over the same span, though FY 2024 was an operating loss of $-1.3M. Per the Roarable RQD rating, ROIC is 17.1%, while the FY 2025 FCF of $-24.5M is consistent with the -23.21% FCF yield. Per the Roarable RQD rating, the Altman Z-Score is 2.09 and the Piotroski F-Score is 4/9, with Debt/Equity at 0.5; the source provides no debt figures in the financials table to corroborate this directly. Per the market data, the operating margin is 7.9% and the net margin is 6.6%.

Recent Catalysts & News Wire Analysis

Q3 2026 earnings: Per the news wire, Organogenesis will report Q3 2026 financial results on November 5. A TradingView item cites a Q3'26 revenue estimate of 52.10M USD.
Clinical publication: Per the news wire, the company announced publication of a diabetic foot ulcer trial.
Analyst target: Per the news wire, a report cites two ratings putting the stock at a USD 2.00 average target, which is well above the $0.82 price in the market data.
Event risk: Per the news wire, an ad-hoc-news.de item frames November 5 as a date that "tests" the stock, making the earnings release the nearest event risk.

Per the Butterfly Supply-Chain Graph, the supply chain is recorded as "NONE," with no butterfly links and no proprietary signals.

Open Questions

What are the company's P/E, EPS, and EV/EBITDA multiples, given that all valuation multiples are absent from the source data?
What is the actual debt balance, given that the financials table reports debt as N/A for every period while the RQD cites Debt/Equity of 0.5?
Does the November 5 Q3 2026 earnings release confirm or contradict the cited $52.10M revenue estimate?
Which institutional holders drive the whale 13F flow score, and what is the direction and size of their positions?
Why does a 17.1% ROIC coexist with a -23.21% FCF yield, and what is driving the gap between accounting returns and cash generation?

ORGO Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Organogenesis Holdings Inc. (Class A) (ORGO) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to ORGO Debate Forum (3) ↓

🟡 MARKET WIRE TradingView • 4h ago

Organogenesis Holdings Inc. Estimates – NASDAQ:ORGO

TradingView report covering Organogenesis Holdings Inc. (Class A) (ORGO) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Quiver Quantitative • 7h ago

Organogenesis Holdings Inc. to Report Third Quarter 2026 Financial Results on November 5 | ORGO Stock News

Quiver Quantitative report covering Organogenesis Holdings Inc. (Class A) (ORGO) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingView • 10h ago

ORGO Q3'26 Earnings: revenue estimate is 52.10M USD

TradingView report covering Organogenesis Holdings Inc. (Class A) (ORGO) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Investing.com UK • 13h ago

Organogenesis announces publication of diabetic foot ulcer trial By Investing.com

Investing.com UK report covering Organogenesis Holdings Inc. (Class A) (ORGO) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE ad-hoc-news.de • 16h ago

Organogenesis stock: Organogenesis published PREPARE results. November 5 tests Organogenesis stock

ad-hoc-news.de report covering Organogenesis Holdings Inc. (Class A) (ORGO) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE ad-hoc-news.de • 19h ago

Two ratings put Organogenesis stock at a USD 2.00 average target

ad-hoc-news.de report covering Organogenesis Holdings Inc. (Class A) (ORGO) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE ad-hoc-news.de • 22h ago

Organogenesis stock holds at EUR 0.73 ahead of Nov. 5 results

ad-hoc-news.de report covering Organogenesis Holdings Inc. (Class A) (ORGO) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo • 21d ago

Organogenesis Announces Publication of Peer-Reviewed PREPARE Trial Results Demonstrating Clinical Benefit of PuraPly®AM for Hard-to-Heal Diabetic Foot Ulcers

CANTON, Mass., Oct. 12, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on product solutions for the Advanced Wound Care and Surgical and Sports Medici

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

ORGO Bull vs. Bear Conversation Board — What's Your Call at $0.77?

🐂 50% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON ORGO 🐻 50% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk ⚖️ DEBATE HOST 🎯 Target: $0.89 (+8.5%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is ORGO (D • RQD 50/100) a Buy at $0.82?

Welcome to the ORGO (Organogenesis Holdings Inc. (Class A)) Roar Pit. Current RQD Composite is 50/100 (Roarable Sell — Underperform / Distribution Warning) in Biotechnology: Pharmaceutical Preparations. Bulls point to capital efficiency (17.1% ROIC), while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

SK SkepticalCFA Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $0.68 (-17.1%)

Spot @ $0.82

Pump the brakes on ORGO — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on ORGO, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Organogenesis Holdings Inc. (Class A) expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

MI MidwestValue Verified K Arena Trader 🐂 BULLISH 🎯 Target: $0.94 (+14.6%)

Spot @ $0.82

ORGO cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on ORGO, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $0.82 (52-wk range $0.72 - $0.90), any beat on forward guidance forces shorts and underweight funds to chase.